135 related articles for article (PubMed ID: 36463701)
1. Influence of primary cancer site on clinical outcomes of anticoagulation for associated venous thromboembolism.
Wysokinski WE; Houghton DE; Vlazny DT; Ashrani AA; Froehling DA; Kamath PS; Meverden RA; Hodge DO; Peterson LG; Lang TR; McBane RD; Casanegra AI
Thromb Res; 2023 Jan; 221():37-44. PubMed ID: 36463701
[TBL] [Abstract][Full Text] [Related]
2. Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes.
Shaw JR; Douketis J; Le Gal G; Carrier M
J Thromb Haemost; 2019 Jul; 17(7):1171-1178. PubMed ID: 31038838
[TBL] [Abstract][Full Text] [Related]
3. Survival Implications of Thrombus Recurrence or Bleeding in Cancer Patients Receiving Anticoagulation for Venous Thromboembolism Treatment.
McBane Ii RD; Vlazny DT; Houghton D; Casanegra AI; Froehling D; Daniels P; Riaz IB; Hodge DO; Wysokinski WE
Thromb Haemost; 2023 May; 123(5):535-544. PubMed ID: 36574777
[TBL] [Abstract][Full Text] [Related]
4. Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Manag Care Spec Pharm; 2015 Oct; 21(10):965-72. PubMed ID: 26402395
[TBL] [Abstract][Full Text] [Related]
5. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis.
Mai V; Tanguay VF; Guay CA; Bertoletti L; Magnan S; Turgeon AF; Lacasse Y; Lega JC; Provencher S
J Thromb Thrombolysis; 2020 Oct; 50(3):661-667. PubMed ID: 32052314
[TBL] [Abstract][Full Text] [Related]
6. Gender differences in patients with venous thromboembolism and five common sites of cancer.
Martín-Martos F; Trujillo-Santos J; Del Toro J; Bura-Riviere A; Lorenzo A; Barillari G; Soler S; Mahè I; Sahuquillo JC; Monreal M;
Thromb Res; 2017 Mar; 151 Suppl 1():S16-S20. PubMed ID: 28262228
[TBL] [Abstract][Full Text] [Related]
7. Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials.
Murphy AC; Koshy AN; Farouque O; Yeo B; Raman J; Kearney L; Yudi MB
Heart Lung Circ; 2022 May; 31(5):716-725. PubMed ID: 34896013
[TBL] [Abstract][Full Text] [Related]
8. Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence.
Jiménez-Fonseca P; Gallardo E; Arranz Arija F; Blanco JM; Callejo A; Lavin DC; Costa Rivas M; Mosquera J; Rodrigo A; Sánchez Morillas R; Vares Gonzaléz M; Muñoz A; Carmona-Bayonas A
Eur J Intern Med; 2022 Jun; 100():33-45. PubMed ID: 35227541
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors for Major Bleeding During Anticoagulation Therapy in Cancer-Associated Venous Thromboembolism - From the COMMAND VTE Registry.
Nishimoto Y; Yamashita Y; Kim K; Morimoto T; Saga S; Amano H; Takase T; Hiramori S; Oi M; Akao M; Kobayashi Y; Toyofuku M; Izumi T; Tada T; Chen PM; Murata K; Tsuyuki Y; Sasa T; Sakamoto J; Kinoshita M; Togi K; Mabuchi H; Takabayashi K; Yoshikawa Y; Shiomi H; Kato T; Makiyama T; Ono K; Sato Y; Kimura T;
Circ J; 2020 Oct; 84(11):2006-2014. PubMed ID: 33012736
[TBL] [Abstract][Full Text] [Related]
10. Use of direct oral anticoagulants and low molecular weight heparin in venous thromboembolism associated with cancer: real-world evidence in Argentina.
Clavijo MM; Ruiz JI; Muñoz C; Vicente Reparaz M de Los A; Acuña MA; Casali CE; Aizpurua MF; Mahuad CV; Zerga ME; Ventura A; Garate GM
Expert Rev Hematol; 2023; 16(12):1143-1149. PubMed ID: 37955142
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
Ross JA; Miller MM; Rojas Hernandez CM
Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience.
Poudel SK; Park DY; Jia X; Wilks M; Pinkava V; O'Brien M; Tripp B; Song JM; McCrae KR; Khorana AA; Angelini DE
J Thromb Haemost; 2020 Mar; 18(3):651-659. PubMed ID: 31808607
[TBL] [Abstract][Full Text] [Related]
13. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
[TBL] [Abstract][Full Text] [Related]
14. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
15. Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study.
Søgaard M; Nielsen PB; Skjøth F; Kjaeldgaard JN; Larsen TB
Cancer Med; 2019 Mar; 8(3):1044-1053. PubMed ID: 30767432
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study.
Bang SM; Kang JH; Hong MH; Ahn JS; Oh SY; Baek JH; Choi YJ; Shin SH; Kim YJ; Gil HY; Park HE; Lee J; Park EL
Clin Appl Thromb Hemost; 2021; 27():1076029620979575. PubMed ID: 33471574
[TBL] [Abstract][Full Text] [Related]
17. Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolism.
Ferrazzini E; Méan M; Stalder O; Limacher A; Rodondi N; Aujesky D
Blood Adv; 2023 Jan; 7(2):205-213. PubMed ID: 35381071
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.
Streiff MB; Milentijevic D; McCrae K; Yannicelli D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J; Khorana AA
Am J Hematol; 2018 May; 93(5):664-671. PubMed ID: 29396864
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Direct Oral Anticoagulants vs. Warfarin and Recurrence After Discontinuation in Patients With Acute Venous Thromboembolism in the Real World.
Hara N; Lee T; Nozato T; Terui Matsuyama M; Okata S; Nagase M; Mitsui K; Nitta G; Watanabe K; Miyazaki R; Nagamine S; Kaneko M; Nakamura T; Nagata Y; Miyamoto T; Obayashi T; Ashikaga T
Circ J; 2022 May; 86(6):923-933. PubMed ID: 34645732
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis.
Camilli M; Lombardi M; Vescovo GM; Del Buono MG; Galli M; Aspromonte N; Zoccai GB; Niccoli G; Montone RA; Crea F; Minotti G
Crit Rev Oncol Hematol; 2020 Oct; 154():103074. PubMed ID: 32911455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
